HIV Infections: all 4,342 studies

Page 28 of 44. Open to participants first (242), then studies with results posted, then the rest; newest registration first within each.

• Peripheral Reservoir of HIV DNA in Monocytes Pivotal to Cognition in HIVCompletedNCT00782808
• Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected PatientsWithdrawnNCT00782301Phase 4
• Hepatitis B and HIV Co-Infection in Patients in UgandaCompletedNCT00782158
• Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1TerminatedNCT00781287Phase 4
• HIV-1 Specific Immune Responses in Thai Individuals With HIV DementiaCompletedNCT00777426
• PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV InfectionCompletedNCT00775424Phase 1
• Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal TissueCompletedNCT00775294Phase 1
• GSK1349572 Drug Interaction Study With Protease InhibitorsCompletedNCT00774735Phase 1
• HIV Risk Reduction in Youth in the BahamasCompletedNCT00774592Not applicable
• Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed ProductCompletedNCT00773708Phase 4
• Maraviroc 300 mg Twice Daily in HIV Negative Male VolunteersCompletedNCT00771823Phase 1
• Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid MetabolismStatus unknownNCT00759070Phase 4
• Influenza Vaccination at a Reduced Dose Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, JerusalemStatus unknownNCT00758212Not applicable
• Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART TherapyTerminatedNCT00757250Phase 1
• Community-based Evaluation of a Pilot PMTCT Project in Kafue DistrictCompletedNCT00753428
• Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of ZambiaCompletedNCT00753324Phase 4
• Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected PatientsCompletedNCT00752037Phase 4
• Immunogenicity and Safety Trial of the HIV-1 Tat VaccineCompletedNCT00751595Phase 2
• Effect of an Online Video-Based Intervention to Increase HIV Testing in Men Who Have Sex With Men in PeruCompletedNCT00751192Not applicable
• Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current TreatmentStatus unknownNCT00751153Phase 4
• Attitudes and Beliefs and the Steps of HIV CareCompletedNCT00749840
• An Affect Management Intervention for Juvenile OffendersCompletedNCT00748800Phase 1
• Assessment of Cytokine Values in Serum and by RT-PCR in HIV-1 Individuals With and Without HAARTCompletedNCT00746473
• IMARA, Adapting SiHLE for Detained African American Adolescent FemalesCompletedNCT00746369Not applicable
• Affect Management Intervention for Early Adolescents Wtih Mental Health ProblemsCompletedNCT00741975Phase 1
• Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected SubjectsStatus unknownNCT00740064Phase 4
• Surveillance and Medical Help for HIV-infected Intravenous Drug Users in and Out of PrisonCompletedNCT00739258
• Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase InhibitorsCompletedNCT00730223Phase 1
• Bone Mineral Density Substudy - An Ancillary Study to MTN-003CompletedNCT00729573
• The Effect of Vitamin D and Calcium on Bone in Pediatric HIVCompletedNCT00724178Phase 2/3
• GSK706769/KALETRA Drug-drug Interaction StudyCompletedNCT00723775Phase 1
• Family Centered Advanced Care Planning for Adolescents With HIV/AIDS and Their FamiliesCompletedNCT00723476Not applicable
• Intervention for (Those) Recently Informed of Seropositive Status (IRISS)CompletedNCT00720733Not applicable
• Maraviroc Compassionate UseWithdrawnNCT00719823Phase 3
• Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral TherapyCompletedNCT00718536Phase 4
• Cerebrospinal Fluid (CSF) Raltegravir SubstudyCompletedNCT00718029
• Social-Psychological Intervention to Improve Adherence to HAARTStatus unknownNCT00716040Not applicable
• Establishing Normal Values for Neuropsychological Testing in HIV-negative ThaisCompletedNCT00713752
• Cohort Study of HIV-1 Incidence Among Clients of the Thai Red Cross AIDS Research Center, Bangkok, ThailandCompletedNCT00713531
• Project ICARE: Intervening for Community Awareness, Respect, & EmpowermentCompletedNCT00712088Not applicable
• GSK706769 Repeat Dose StudyCompletedNCT00711386Phase 1
• Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve PatientsCompletedNCT00711230Phase 2
• Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk PopulationsCompletedNCT00710060Phase 3
• Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector InjectionCompletedNCT00709605Phase 1
• Effectiveness of Antiretroviral Therapy During Acute HIV InfectionCompletedNCT00705926Phase 1
• Effectiveness of an HIV Prevention Program That Targets the Inner Workings of High-risk Social NetworksCompletedNCT00705705Phase 2
• Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)CompletedNCT00705419
• VENICE Study Nevirapine Full Dose/Dose EscalationCompletedNCT00704249Phase 4
• Durability of Nevirapine-Based Antiretroviral RegimenCompletedNCT00703898Phase 4
• Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With MaravirocCompletedNCT00703586Phase 1
• Response to Standard HIV Treatment in Bamako, MaliCompletedNCT00703404
• The Human Immunodeficiency Virus and Osteopathic Manipulation Evaluation StudyCompletedNCT00703248Not applicable
• Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral TherapeuticsCompletedNCT00702013
• Feasibility Study of a Vaginal Ring for Delivery of TMC120 (Dapivirine)CompletedNCT00700284Phase 1
• Effectiveness of Communication Technology in Disseminating HIV Prevention Training to Non-governmental OrganizationsCompletedNCT00698529Phase 2
• Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated TuberculosisCompletedNCT00698334Phase 3
• A School-Based HIV/STD Prevention Program to Reduce Risky Sexual Behaviors Among Adolescents in LiberiaCompletedNCT00698321Not applicable
• Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug CombinationsCompletedNCT00697892Phase 1
• Trial of Cognitive Behavioral Therapy to Reduce Antiretroviral Therapy Side EffectsCompletedNCT00696839Not applicable
• Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy AdultsCompletedNCT00695877Phase 1
• Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infectionStatus unknownNCT00692809
• Culturally-Tailored HIV Risk Reduction for African-American MSMCompletedNCT00691561Not applicable
• A Behavioral Intervention to Reduce Sexual Risk Among African-American Men Who Have Sex With MenCompletedNCT00691496Not applicable
• A Network Intervention for Reducing Sexual Risk for HIV With African American Men Who Have Sex With Men (AA MSM)CompletedNCT00691041Not applicable
• Proyecto SOL: A Risk Reduction Intervention for Hispanic Men Who Have Sex With Men (MSM)CompletedNCT00690976Not applicable
• No Excuses/Sin Buscar Excusas Intervention to Reduce Latino Men's HIV RisksCompletedNCT00690690Phase 2/3
• The Detection of Drug-Resistant HIV-1 in TaiwanStatus unknownNCT00690001
• Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-PartumWithdrawnNCT00689910
• Pilot Trial of a Synbiotic in HIV+ PatientsCompletedNCT00688311Not applicable
• A Long Term Safety Study of Apricitabine in HIV-infected PatientsWithdrawnNCT00686270Phase 3
• HIV Treatment-Readiness Measure (HTRM) ValidationCompletedNCT00686049
• HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in SpainCompletedNCT00685191Phase 4
• Neurocognitive Assessment in Youth Initiating HAARTCompletedNCT00683579
• Preventing HIV/Aids in Drug Abusing YouthCompletedNCT00680719Phase 1
• A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV InfectionCompletedNCT00679497Phase 1
• Study of Provider Computer Alerts Designed to Improve Delivery of HIV CareCompletedNCT00678600Not applicable
• Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive PatientsCompletedNCT00677300Phase 4
• An Open-Label Treatment Protocol to Provide Continued Elvucitabine TreatmentCompletedNCT00675844Phase 2
• Enhancing Communication and HIV OutcomesCompletedNCT00675610Phase 3
• Impact of Peer Health Workers and Mobile Phones on HIV CareCompletedNCT00675389Not applicable
• Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, UgandaStatus unknownNCT00674921Phase 4
• Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in ThailandCompletedNCT00672412Phase 1/2
• Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIVCompletedNCT00672191Phase 2
• Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)CompletedNCT00670839Phase 3
• HIV Vertical Transmission in VietnamCompletedNCT00669604
• A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVPCompletedNCT00669487Phase 3
• Bioequivalence Study of Didanosine in Children Treated for HIVSuspendedNCT00668356Phase 2
• Raltegravir as Early Therapy in African-Americans Living With HIV StudyCompletedNCT00667433Phase 1
• Sex, Aging and Antiretroviral PharmacokineticsCompletedNCT00666055
• Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)CompletedNCT00665951Phase 1
• The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)CompletedNCT00665717Phase 1
• Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV PatientsTerminatedNCT00661349Phase 4
• Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)CompletedNCT00660972Phase 1
• A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744CompletedNCT00659191Phase 1
• Molecular Diversity of HIV-1 Group O Strains and Treatment Management in CameroonCompletedNCT00658346
• Metabolic Effects of Enfuvirtide in Healthy VolunteersCompletedNCT00657761Phase 4
• Adult Sexual Risk Behavior Among Women With a History of Childhood Sexual AbuseCompletedNCT00653575
• Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in VietnamCompletedNCT00651066Phase 2
• Novel Internet-Based Interventions to Reduce Sexual Risk Among Men Who Have Sex With MenStatus unknownNCT00649701Phase 1
• Safety and Efficacy of Kaletra in ARV Therapy Experienced PatientsCompletedNCT00648999Phase 4

← HIV Infections overview